GlassScriptPhysician profile
Gary C Rosenblum
NPI 1194706556
$197,299.91
in general payments reported to CMS, 2019-2025
7 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,085 · 2020: $7,020 · 2021: $31K · 2022: $44K · 2023: $33K · 2024: $38K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $5,036 · Consulting Fee: $4,000 · Travel and Lodging: $1,855 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,000.00 |
| Food and Beverage | $5,035.65 |
| Consulting Fee | $4,000.00 |
| Travel and Lodging | $1,855.39 |
| Education | $114.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169,214.43 | 2019-2025 | Rinvoq, Skyrizi |
| Aurinia Pharma U.S., INC. | $26,586.88 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $1,138.77 | 2019-2021 | |
| Janssen Biotech, INC. | $218.96 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $122.19 | 2022 | |
| Medexus Pharma, INC. | $18.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Rosenblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.